- Axplora announced more than €100 million in investments across its global manufacturing network in 2025.
- The programme includes major expansions at sites in France, Italy, and India, strengthening capabilities in small molecules and ADC manufacturing.
Axplora, a global manufacturer of small molecule active pharmaceutical ingredients (APIs), announced that the total value of investments initiated across its global network in 2025 will exceed €100 million.
The investment programme covers expansions in multiple regions, including €60 million for its Mourenx site in France, €35 million at Gropello in Italy, and €8.5 million at Vizag in India. Earlier this year, Axplora also expanded its antibody-drug conjugate (ADC) manufacturing capabilities in Le Mans, France.
According to the company, these multi-year projects are designed to embed long-term capacity and capability within its global operations. The large-scale initiative in Mourenx is also providing opportunities for technical collaboration with customers on complex projects, with learnings being shared across Axplora’s nine global sites.
The company noted that while emerging modalities such as GLP-1 peptides and ADCs offer strong growth potential, small molecules continue to form the foundation of pharmaceutical manufacturing. Axplora’s €100 million programme aims to balance these priorities by reinforcing large-scale small molecule production while expanding into advanced therapeutic areas.
“Announcing €100 million of investment this year is a landmark for Axplora – but more than just a number, it represents the trust our customers place in us and the scale of our commitment to them and their patients.”
Martin Meeson, CEO of Axplora
